Wire · opportunities
FDA Approves Lucamzi as Ranibizumab Biosimilar to Lucentis for Retinal Diseases
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
The FDA approved Lucamzi, a biosimilar to Lucentis, for treating wet AMD and other retinal diseases, with a planned US launch in 2027. Clinical trials showed equivalent efficacy and comparable safety to the reference drug, signaling expanded treatment options and potential market competition.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You now face a more competitive field in anti-VEGF retinal therapies as a second FDA-approved biosimilar will push pricing and access. Adjust your market approach to anticipate pressure on legacy drug sales and new customer outreach.
◆ Coverage
1 source · 2 Nov 2026
◆ Related on Wire
◆ Topics